Skip to content
Peptide Atlas
All peptides

Thymalin

Tier 3 · Reported use
Also known as Thymus peptide complex · Thymalinum

The strongest evidence present is Tier 1: a large observational cohort of 266 elderly persons over 6-8 years (variously described as observational and, by one vendor, as a single adequately-powered RCT, PMID 14523363) plus tier-1 reviews and psoriasis/endometrial clinical studies. However, most human data are observational rather than blinded RCTs, nearly all research originates from a single Russian group (Khavinson laboratory) with limited independent Western replication, and pharmacokinetic and specific mortality-percentage figures come only from tier-3 vendor material. Thymalin is an undefined, batch-variable bovine thymus extract with a theoretical prion/contamination risk and no FDA/EMA approval.

Half-life
~7 h
Routes
Intramuscular injection · Subcutaneous injection · Parenteral (lyophilized injectable)
Goals
Immune support / immunomodulation · Longevity / anti-aging · Infection recovery · Inflammation reduction · Hematopoietic recovery (post-chemotherapy / radiation)
Cost / mg
Not recorded

How it works

Sources describe Thymalin as a polypeptide complex isolated from the thymus gland of young calves that acts as an immune regulator. Khavinson-group sources report it contains short peptides (the dipeptides EW and KE and the tripeptide EDP) that are said to bind DNA and histone proteins to influence which genes are switched on, thereby helping bone-marrow-derived precursor cells mature into T-lymphocytes and restoring balance to the immune system. Sources report it dampens pro-inflammatory signaling and enhances the activity of immune cells such as natural killer cells and phagocytes. Because it is a mixture rather than a single defined molecule, one vendor characterizes its effects as broader but less targeted than single-sequence peptides.

Overview

Overview

Sources report that Thymalin (also called Thymus peptide complex or Thymalinum) is a polypeptide complex isolated from the thymus gland of young calves (bovine calf thymus) (src-3, src-6, src-7, src-8). Vendor sources report it was developed in the 1970s in the Soviet Union by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in Leningrad, with a tier-2 study noting Khavinson characterized these peptides from 1973 onwards (src-7, src-9, src-12, src-22). Sources give varying regulatory dates: one states first USSR approval in 1982 for immunodeficiency states, others say Russia since the 1980s or 1970s (src-7, src-9, src-13, src-4); Khavinson-group studies and a vendor cite a Russian registration number LS-000267 dated February 26, 2010 (src-3, src-6, src-7).

A tier-1 review describes Thymalin as a polypeptide drug used for diseases associated with immune dysfunction, viral and bacterial infections, normalization of regeneration, immunodepression, and depression of hematopoiesis following chemical and radiotherapy (src-1).

Composition and classification

Multiple Khavinson-group sources report Thymalin's components include the dipeptide EW (thymogen), the dipeptide KE, and the tripeptide EDP (src-1, src-3, src-6, src-7, src-14). A vendor reports the EW dipeptide has molecular formula C16H19N3O5 and molecular weight 333.34 g/mol (src-7). Multiple vendor sources describe Thymalin's molecular weight as roughly 1,000-10,000 Da\of of short peptides of 2-8 amino acids (src-7, src-8, src-12, src-9). Khavinson-group sources state manufacturing uses special extraction and purification that completely degrades macromolecular proteins while preserving peptides under 10 kDa (src-2); a vendor reports it is produced by acid hydrolysis of bovine calf thymus tissue followed by ultrafiltration to isolate peptides below 10 kDa (src-7). A vendor classes Thymalin among the cytomedin family of short peptide bioregulators that influence DNA transcription and cellular differentiation (src-13).

Reported mechanism

Khavinson-group studies report that the short peptides KE, EW and EDP can specifically bind double-stranded DNA and/or histone proteins to regulate gene expression, immune-protein synthesis, gerontogene activity and stem-cell differentiation (src-3, src-6). A tier-2 docking study reports GGAG as the preferred DNA sequence for EW and GCGC for KE, and identified AKT1/AKT2 as potential target genes involved in cytokine-storm development (src-20). In vitro, Thymalin and its EW and KE dipeptides reduced IL-1beta, IL-6 and TNF-alpha synthesis in human PBMCs by 1.4-6.0 times (src-20), and a THP-1 monocyte study reported inhibition of LPS-stimulated TNF and IL-6 and induction of TNF tolerance (src-22). Khavinson-group and tier-2 reports describe modulation of hematopoietic stem cell markers (CD44, CD117 down; CD28 up) interpreted as stimulating differentiation into mature T-lymphocytes (src-3, src-6, src-18, src-4). A tier-1 review states the immunoprotective effect is expressed as restoration of T and B lymphocytes and their subpopulations, increased functional activity and increased phagocytosis (src-1). One vendor theorizes its polypeptide composition produces broader but less targeted effects than single-sequence peptides (src-10, src-18).

Reported clinical and preclinical evidence

A tier-1 study reports that in 266 elderly and older persons observed over 6-8 years, Thymalin and Epithalamin improved indices of the cardiovascular, endocrine, immune and nervous systems, homeostasis and metabolism (src-2, src-19, src-30). The same dataset reports Thymalin alone produced a 2.0-2.1-fold decrease in mortality versus control, Epithalamin alone a 1.6-1.8-fold decrease, the combination a 2.5-fold decrease, and the combination applied annually for 6 years a 4.1-fold decrease (src-2, src-19, src-30). It is worth noting these primary sources describe the study as observational, while one vendor (src-4) characterizes it as a single adequately-powered RCT (PMID 14523363). Separately, a tier-3 vendor (src-9) characterizes the trial as producing a 45% reduction in cardiovascular mortality and a 28% reduction in all-cause mortality ,'s figures that appear only on that single site. Tier-1 studies also report Thymalin was associated with a 2.0-2.4-fold decrease in acute respiratory disease incidence and reduced incidence of ischemic heart disease, hypertension, deforming osteoarthrosis and osteoporosis (src-1, src-2, src-19, src-30).

Khavinson-group studies report that in COVID-19, Thymalin plus standard therapy (n=36) produced more rapid clinical improvement than standard therapy alone (n=44), with faster recovery from lymphopenia and normalization of C-reactive protein, D-dimer, lymphocyte and NK-cell counts, and that it halved hospital mortality in older patients with severe COVID-19 (src-3, src-6, src-14). A case report describes a 2-fold increase in lymphocytes, 7-fold in eosinophils, and reductions of 8x in CRP, 2.5x in IL-6 and 7.2x in D-dimer (src-3, src-6). A tier-2 study describes efficacy in acute respiratory distress syndrome and COPD and in complex therapy of severe COVID-19 (src-20, src-18). Khavinson-group sources report use in hepatitis A and B, erysipelas, meningococcal infection, typhoid fever, pneumonia and cavernous pulmonary tuberculosis (src-3, src-6).

Additional tier-1 clinical reports include a study of 104 psoriasis patients showing decreased T-helper/T-suppressor ratios versus control, and 27 psoriatics treated with Thymalinum plus Natrii nucleinas whose ratio rose from 1.0 to 1.74 with shorter rash regression and prolonged remissions (src-24), and use of Thymalinum with norcolut and myelopidum in 55 patients with hyperplastic endometrial processes (src-25). Animal studies (mice, rats, Drosophila, 1971-2001) are reported to prolong lifespan and inhibit age-related disorders (src-2), with a vendor citing 20-30% lifespan extension in animal models (src-13). Tier-2 animal studies report a pronounced antitumor effect against transplanted sarcoma 45 in rats (src-21) and activation of reparative osteogenesis around a jaw bone defect in WAG rats (src-26). Tier-3/4 sources describe potential roles in correcting radiative immunodeficiencies (src-17), dental and maxillofacial pathology (src-29), and athlete recovery and anti-aging protocols (src-15).

Evidence caveats

A vendor profile characterizes the overall evidence base as roughly 73% preclinical and 27% clinical, with an Evidence Score of 57/100, noting most studies come from a single Russian group (the Khavinson laboratory) with limited Western replication (src-4); another vendor counts 234 published studies and notes Thymalin is approved in Russia but never evaluated by Western regulators and is an undefined bovine thymus extract with batch-consistency challenges (src-8). Readers should note that nearly all evidence originates from one research group, most human data are observational rather than blinded RCTs, and sources disagree on whether Thymalin is a natural extract or synthetic and on its approval dates.

What the research shows

269 findings extracted from the 30 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 1 human trial finding, 59 human study findings, 7 animal findings, 2 in vitro findings, 17 expert opinion findings and 1 theoretical finding.

  • human trialSingle adequately-powered Russian RCT (n=266, 6-8y, PMID 14523363) showed approximately 2-fold mortality and respiratory-illness reductions in elderly patients24

  • human studyThymalin normalizes the functions of the immune system and stimulates regeneration and hematopoiesis if suppressed1

  • human studyUse of thymalin reduced incidence of acute respiratory diseases in elderly and senile people1

  • human studyThymalin treatment in patients with acute lung abscesses led to decrease in systemic inflammatory response syndrome, decrease in plasma fibrinolytic activity, and cessation of hypercoagulation1

  • human studyThymalin has shown geroprotective properties in animal experiments and clinical studies1

  • human studyThymalin contributed to restoration of immune system functions and reduced mortality in elderly patients1

  • human studyThymalin and Epithalamin normalized basic functions of the human organism, improving indices of cardiovascular, endocrine, immune and nervous systems, homeostasis and metabolism in 266 elderly and older persons during 6-8 years2

  • human studyThymalin treatment resulted in 2.0-2.1-fold decrease in mortality rate compared to control2

Show the remaining 79

  • human studyThymalin plus Epithalamin combination resulted in 2.5-fold decrease in mortality rate compared to control2

  • human studyThymalin in combination with Epithalamin applied annually for 6 years resulted in 4.1-fold decrease in mortality rate compared to control2

  • human studyThymalin treatment associated with 2.0-2.4-fold decrease in acute respiratory disease incidence2

  • human studyThymalin treatment reduced incidence of ischemic heart disease, hypertension disease, deforming osteoarthrosis and osteoporosis2

  • human studyPatients administered Thymalin with standard therapy manifested more rapid clinical improvement compared to standard therapy only3

  • human studyThymalin produced higher proportions of recovery from lymphopenia3

  • human studyThymalin produced faster normalization of C-reactive protein, D-dimer, lymphocyte and NK-cell counts3

  • human studyThymalin halved hospital mortality in older patients with severe COVID-193

  • human studyAdministration of Thymalin reduced the incidence of acute respiratory infections in senior patients 2.0-2.4-fold3

  • human studyThymalin reduced mortality in senior patients over a 6-year observation period3

  • human studyIn severe COVID-19 case, Thymalin increased blood lymphocytes 2-fold3

  • human studyIn severe COVID-19 case, Thymalin increased eosinophils 7-fold3

  • human studyIn severe COVID-19 case, Thymalin reduced C-reactive protein 8 times3

  • human studyIn severe COVID-19 case, Thymalin reduced IL-6 2.5 times3

  • human studyIn severe COVID-19 case, Thymalin reduced D-dimer 7.2 times3

  • human studyThymalin is effective in case of various infectious diseases including hepatitis A and B, erysipelas, meningococcal infection, typhoid fever4

  • human studyThymalin is effective in acute respiratory diseases, pneumonia of various origins, cavernous pulmonary tuberculosis4

  • human studyAdministration of Thymalin reduced the incidence of acute respiratory infections in senior patients 2.0–2.4-fold4

  • human studyThymalin reduced mortality in senior patients over a 6-year observation period4

  • human studyPatients administered with Thymalin against the background of standard therapy (n=36) manifested more rapid clinical improvement compared to standard therapy only (n=44)4

  • human studyThymalin produced higher proportions of recovery from lymphopenia compared to standard therapy alone4

  • human studyThymalin produced faster normalization of C-reactive protein, D-dimer, number of lymphocytes and NK-cells in the blood compared to standard therapy alone4

  • human studyThymalin halved hospital mortality in older patients with severe COVID-194

  • human studyIn a case study, combination of Thymalin and comprehensive treatment increased blood lymphocyte concentration 2-fold and eosinophils 7-fold4

  • human studyIn a case study, Thymalin combination therapy reduced C-reactive protein, IL-6, and D-dimer concentration by 8, 2.5 and 7.2 times respectively4

  • human studyThymalin improved cardiovascular system indices in 266 elderly and older persons over 6-8 years5

  • human studyThymalin improved endocrine system indices in elderly and older persons5

  • human studyThymalin improved immune system indices in elderly and older persons5

  • human studyThymalin improved nervous system indices in elderly and older persons5

  • human studyThymalin restored homeostasis and improved metabolism in elderly and older persons5

  • human studyThymalin treatment resulted in 2.0-2.4-fold decrease in acute respiratory disease incidence compared to control5

  • human studyThymalin treatment reduced incidence of ischemic heart disease clinical manifestations compared to control5

  • human studyThymalin treatment reduced incidence of hypertension disease compared to control5

  • human studyThymalin treatment reduced incidence of deforming osteoarthrosis compared to control5

  • human studyThymalin treatment reduced incidence of osteoporosis compared to control5

  • human studyThymalin-treated group showed 2.0-2.1-fold decreased mortality rate during observation period compared to control5

  • human studyThymalin in combination with Epithalamin treated annually for 6 years resulted in 4.1-fold decreased mortality rate compared to control5

  • human studyThymalin and Epithalamin improved indices of the cardiovascular, endocrine, immune, and nervous systems, homeostasis, and metabolism in elderly and older persons6

  • human studyThymalin treatment resulted in 2.0-2.4-fold decrease in acute respiratory disease incidence compared to control group6

  • human studyThymalin treatment reduced incidence of ischemic heart disease clinical manifestations, hypertension, deforming osteoarthrosis, and osteoporosis compared to control group6

  • human studyThymalin-treated patients showed 2.0-2.1-fold decrease in mortality rate during observation period compared to control group6

  • human studyThymalin combined with Epithalamin showed 2.5-fold decrease in mortality compared to control group6

  • human studyThymalin combined with Epithalamin applied annually for 6 years resulted in 4.1-fold mortality decrease compared to control level6

  • human studyThe combined treatment scheme of norcolut with immune modulators thymalinum and myelopidum increased treatment effectiveness for hyperplastic endometrial processes7

  • human studyThymalinum received in addition to antipsoriatic therapy resulted in an increase in T-helper/T-suppressor ratio and was followed by a favorable clinical course (shorter periods of skin rash regression, prolonged remissions)8

  • human studyThymalin is an immunomodulatory drug containing a polypeptide extract of thymus that has demonstrated efficacy in the therapy of acute respiratory distress syndrome and chronic obstructive pulmonary disease, as well as in complex therapy related to severe COVID-19 in middle-aged and elderly patients10

  • human studyClinical trials of Thymalin have been conducted15

  • human studyClinical studies on severe COVID-19 patients demonstrated that Thymalin added to complex therapy led to normalization of lymphocyte and platelet counts and hemostasis indicators16

  • human studyThymalin has demonstrated efficacy in the complex therapy of acute respiratory distress syndrome (ARDS) and chronic obstructive pulmonary disease (COPD)16

  • human studyIn the longest human clinical trial ever conducted on a therapeutic peptide, thymalin reduced cardiovascular mortality by 45% and all-cause mortality by 28% over a 6-year follow-up period in elderly patients17

  • human studyThe Khavinson & Morozov 6-year trial used thymalin alongside epithalon and produced 28% reduction in all-cause mortality and 45% reduction in cardiovascular mortality17

  • human studyResearch from the Khavinson group reports reduced mortality with combined Thymalin and Epithalamin treatment in elderly subjects followed for 6-8 years18

  • animalAnimal studies on mice, rats and Drosophila melanogaster demonstrated that Thymalin significantly prolonged life span and inhibited age-related disorders2

  • animalThymalin injection in soft tissues surrounding a bone defect in the lower jaw, filled with hydroxyapatite-containing osteotropic material (bone graft 'Biomin GT'), activates reparative osteogenesis9

  • animalPronounced antitumor effect of Thymalin in doses lower than the therapeutic doses was shown in experiments on albino outbred male rats with transplanted sarcoma 4513

  • animalTumor growth arrest and its regression were observed in more than half of animals13

  • animalIn other cases, growth was suppressed by 78%13

  • animalTumor regression was accompanied by the development of stable antistress adaptation reactions of calm and elevated activation13

  • animalThymalin extends lifespan in animal models by 20–30%16

  • in vitroIn vitro model of an inflammatory reaction demonstrated that Thymalin and EW and KE dipeptides reduced the synthesis of IL-1β, IL-6, and TNF-α cytokines in human peripheral blood mononuclear cells by 1.4-6.0 times10

  • in vitroKhavinson VKh et al. (Russia, 2020) demonstrated HSC differentiation markers in vitro (PMID:33237528)24

  • expert opinionThymalin has been studied in thousands of patients for its ability to restore immune function and delay aging16

  • expert opinionThymalin has accumulated over 40 years of clinical data across immune restoration, anti-aging, and infection management17

  • expert opinionImprovement of red and white blood cell counts after suppression20

  • expert opinionClinical studies demonstrate thymalin's efficacy in treating age-related immune decline with T-cell restoration20

  • expert opinionResearch indicates potential benefits in tuberculosis and chronic viral infections with faster recovery20

  • expert opinionPotential benefits in pneumonia with reduced relapse rates20

  • expert opinionEnhanced vaccine response in elderly patients20

  • expert opinionThymalin demonstrates protective effects against chemotherapy-induced immune suppression20

  • expert opinionProtection against radiation therapy hematopoietic damage20

  • expert opinionPreclinical evidence supports potential benefits in age-related immune system decline20

  • expert opinionThymalin appeared to halve hospital mortality rates in older patients with severe COVID-1921

  • expert opinionEDP tripeptide is associated with normalization of immunograms in clinical settings, with reported efficacy of 82% versus 56% in controls23

  • expert opinionEvidence comes primarily from Russian studies with limited Western replication24

  • expert opinionMost studies from single Russian research group (Khavinson laboratory)24

  • expert opinionThymalin is useful in complex treatment of dental diseases in the elderly25

  • expert opinionPineal peptides (Epithalamin, Epitalon) had more effective geroprotective effect on thymus involution compared with geroprotective effect of thymic peptides (Thymalin, Thymogen) on involution of pineal gland26

  • expert opinionPineal peptides (epithalamin, epitalon) had more effective geroprotective effect on thymus involution in comparison with geroprotective effect of thymic peptides (thymalin, thymogen) on involution of pineal gland27

  • theoreticalThymalin is effective in therapy of acute respiratory syndrome, chronic obstructive bronchitis, and other immunopathology12

How it works

Based on 12 human study findings, 10 animal findings, 20 in vitro findings, 46 expert opinion findings and 11 theoretical findings.

  • human studyImmunoprotective effect of thymalin is expressed in restoration of T and B lymphocytes and their subpopulations, increase in functional activity, and increased phagocytosis1

  • human studyThe molecular mechanism of Thymalin immunoprotective action is due to short peptides KE, EW, EDP in its composition3

  • human studyShort peptides can specifically bind to double-stranded DNA and/or histone proteins and regulate gene expression3

  • human studyThymalin regulates synthesis of immune system proteins and activity of gerontogenes3

  • human studyThymalin stimulates stem cell differentiation3

  • human studyThymalin prevents cytokine storm by reducing pro-inflammatory cytokines IL-1α, IL-6, IL-8, TNF-α3

  • human studyThymalin reduces intensity of intravascular blood coagulation in hypercoagulability syndrome3

  • human studyThymalin is accumulated in epithelial cells of the human respiratory tract during early embryogenesis4

Show the remaining 91

  • human studyThymalin prevents the cytokine storm which develops during COVID-19, reducing the concentration of pro-inflammatory cytokines IL-1α, IL-6, IL-8, TNF-α in the blood4

  • human studyThymalin reduces the intensity of intravascular blood coagulation in the development of hypercoagulability syndrome4

  • human studyThymalinum is an immune modulator7

  • human studyIn all forms of psoriasis with a slight alteration in T-lymphocyte content a significant dysbalance of T-helpers and T-suppressors was found that brought about a decrease in the correlation ratio T-helpers/T-suppressors8

  • animalThymalin stimulates reparative osteogenesis by rapid cleaning of bone defect cavity from necrotic tissues and hematoma fragments9

  • animalThymalin injection decreases the number of neutrophil leukocytes in the bone defect area9

  • animalThymalin injection increases the number and morphofunctional state of monocytes, macrophages, and lymphocytes9

  • animalThymalin injection increases the number and morphofunctional state of cells of fibroblastic differon9

  • animalThymalin injection produces balanced change in number and morphofunctional state of osteoblasts and osteoclasts depending on stage of reparative osteogenesis9

  • animalThymalin injection activates hematopoietic processes in lamellar bone tissue from the regenerate9

  • animalThymalin injection activates bone tissue mineralization processes9

  • animalSignificant increase in lymphoproliferative activity and the content of tissue basophils and plasmocytes in the thymus lobules was observed13

  • animalThymalin stimulates immunity15

  • animalThymalin's ability to stimulate immunity is associated with anticarcinogenic and geroprotector activities15

  • in vitroIn study on human hematopoietic blood stem cells, Thymalin decreased CD44 expression 2.8-fold3

  • in vitroShort peptides in Thymalin can specifically bind to double-stranded DNA and/or histone proteins and regulate gene expression, synthesis of immune system proteins, activity of gerontogenes, and stimulate stem cell differentiation4

  • in vitroIn a study on human hematopoietic blood stem cells, Thymalin decreased the expression of CD44 on HSC 2.8-fold4

  • in vitroIn a study on human hematopoietic blood stem cells, Thymalin reduced the expression of CD117 on HSC 2.2-fold4

  • in vitroIn a study on human hematopoietic blood stem cells, Thymalin reduced the expression of CD28 on HSC 6.9-fold4

  • in vitroKE stimulates cellular immunity and nonspecific resistance in organisms, exerting an activating effect on macrophages, blood lymphocytes, thymocytes, and neutrophils10

  • in vitroUsing molecular docking, GGAG was found to be the best dsDNA sequence in the classical B-form for binding the EW dipeptide, while GCGC is the preferred dsDNA sequence in the curved nucleosomal form for the KE dipeptide10

  • in vitroCluster analysis revealed that potential target genes for the EW and KE peptides encode the AKT1 and AKT2 proteins involved in the development of the cytokine storm10

  • in vitroThymalin peptide complex can modulate key proliferative patterns, increasing tyrosine phosphorylation of mitogen-activated cytoplasmic kinases in human monocytic THP-1 cells11

  • in vitroThymalin peptide complex inhibits the expression of TNF and pro-inflammatory IL-6 cytokine stimulated by LPS on terminally differentiated THP-1 cells11

  • in vitroThymalin peptide complex reduces cell adhesion in THP-1 cells incubated on a layer of activated endothelial cells (HUVECs activated by LPS)11

  • in vitroThymalin peptide complex acts as a natural inducer of TNF tolerance in monocytes and as an anti-inflammatory molecule during inflammatory and microbial-mediated activity11

  • in vitroThymalin reduced the expression of CD44 (stem cell marker) by 2-3 times12

  • in vitroThymalin reduced the expression of CD117 (molecule of the intermediate stage of HSC differentiation) by 2-3 times12

  • in vitroThymalin increased the expression of CD28 (marker of mature T lymphocytes) by 6.8 times12

  • in vitroThymalin stimulated differentiation of CD117 cells into mature CD28 T lymphocytes12

  • in vitroThymalin could modify radiation-induced cytogenetic effects in peripheral blood lymphocytes of healthy individuals14

  • in vitroThymalin exerts protective or sensitizing action dependent on its concentration, cell radiosensitivity, dose of irradiation, and relative biologic effectiveness of ionizing radiation14

  • in vitroA dipeptide specific for the thymus stimulates in vitro outgrowth of thymus explants15

  • in vitroThymalin reduced CD44/CD117 expression 2-3 fold and increased CD28 (mature T-cell marker) by 6.8 fold, indicating stimulation of HSC differentiation into mature T lymphocytes24

  • expert opinionThymalin components include EW dipeptide (thymogen), dipeptide KE, and tripeptide EDP1

  • expert opinionShort peptides regulate gene expression and synthesis of heat-shock protein, cytokines, fibrinolysis, gerontogenes, and differentiation, proliferation, apoptosis of cells1

  • expert opinionThymalin is obtained from thymic peptides isolated according to special technology to correct disorders from age-related thymic involution2

  • expert opinionThe molecular mechanism of the Thymalin immunoprotective action is due to the effects of the short peptides KE, EW, EDP in its composition4

  • expert opinionThymalin is a complex mixture of peptides derived from the thymus gland16

  • expert opinionThymalin operates as a multi-system bioregulator, promoting immune balance, hematopoietic regeneration, and anti-aging signaling16

  • expert opinionThymalin is a polypeptide complex derived from purified extracts of the thymus gland of young calves16

  • expert opinionThymalin belongs to a class of compounds called cytomedins—short peptide bioregulators that influence DNA transcription and cellular differentiation16

  • expert opinionThymalin regulates the maturation and differentiation of T-lymphocyte precursors originating in the bone marrow16

  • expert opinionThymalin helps normalize the cytokine profile, suppressing excessive pro-inflammatory mediators (IL-1 beta, IL-6, TNF-alpha) during a cytokine storm16

  • expert opinionThymalin stimulates the production of various blood cells (leukocytes, monocytes, platelets), supporting bone marrow recovery after suppression16

  • expert opinionThymalin exerts its effects through gene-level regulation, influencing cellular aging16

  • expert opinionThymalin restores immune competence by stimulating T-lymphocyte differentiation, modulating natural killer cell activity, and correcting age-related immune decline17

  • expert opinionThymalin is a polypeptide complex extracted from the thymus gland of young calves, containing short peptides (2–8 amino acids)17

  • expert opinionThymalin enhances T-cell differentiation and maturation, increases the CD4/CD8 T-cell ratio, modulates natural killer cell activity, regulates cytokine balance, and supports the expression of genes associated with immune function and longevity17

  • expert opinionResearch suggests Thymalin may influence T-cell differentiation and immune cell function18

  • expert opinionResearch suggests Thymalin stimulates differentiation and maturation of T-lymphocytes (CD4+ and CD8+), restores T/B lymphocyte ratios, enhances NK cell activity, increases phagocytic function, and normalizes circulating immune complexes18

  • expert opinionPolypeptide composition means broader but less targeted effects vs single-sequence peptides19

  • expert opinionThymalin is a polypeptide complex derived from the thymus gland of young calves, containing short peptides (2-8 amino acids) that regulate gene expression in immune and hematopoietic cells20

  • expert opinionThymalin exhibits unique properties as a multi-peptide complex that regulates immune cell differentiation and maintains bioactivity across various clinical applications, with decades of clinical use in Eastern Europe20

  • expert opinionThymalin activates immune development pathways, leading to stimulation of hematopoietic stem cell differentiation into T-lymphocytes20

  • expert opinionEnhancement of mature T-helper and T-suppressor cell proliferation20

  • expert opinionRestoration of immune balance and adaptive immunity20

  • expert opinionThymalin modulates genes involved in apoptosis and cell cycle regulation20

  • expert opinionThymalin influences immune signaling by regulation of cytokine production and inflammatory balance20

  • expert opinionReduction of chronic inflammation markers20

  • expert opinionThymalin demonstrates hematopoietic enhancement through stimulation of erythropoiesis and granulopoiesis20

  • expert opinionThymalin, a peptide derived from the thymus gland, can play a vital role in modulating the immune response, which is often dysregulated in severe COVID-19 cases, leading to a 'cytokine storm'21

  • expert opinionThe mechanism behind Thymalin's effectiveness in COVID-19 likely stems from its ability to regulate gene expression and immune protein synthesis21

  • expert opinionThe peptides within Thymalin, such as EW, KE, and EDP, are thought to interact with DNA and histones, influencing the production of cytokines and regulating immune cell differentiation21

  • expert opinionThymalin's effects on normalizing the immune status indicators correlate with its known immunoprotective and geroprotective properties21

  • expert opinionThe preparation contains a mixture of low-molecular-weight peptides (up to 10 kDa), with three principal bioactive components: the dipeptide L-Glu-L-Trp (EW), the dipeptide Lys-Glu (KE), and the tripeptide Glu-Asp-Pro (EDP)23

  • expert opinionThymalin is produced through acid hydrolysis of bovine calf thymus tissue followed by ultrafiltration to isolate peptides below 10 kDa23

  • expert opinionEW peptide activates T-cell differentiation, modulates cyclic nucleotide balance (cAMP/cGMP), and enhances neutrophil chemotaxis and phagocytosis23

  • expert opinionKE peptide demonstrates selective binding to TCGA DNA sequences and regulates expression of genes involved in immune cell proliferation23

  • expert opinionThymalin peptides interact with thymic epithelial cells, promoting thymocyte selection and maturation and normalizing the number and ratio of T and B lymphocytes23

  • expert opinionThymalin is a thymic peptide complex derived from calf thymus extract containing multiple peptides claimed to restore immune function24

  • expert opinionThymalin promotes hematopoietic stem cell differentiation into mature T-lymphocytes by modulating CD44, CD117, and CD28 expression markers24

  • expert opinionThymalin suppresses pro-inflammatory cytokines (IL-1B, IL-6, TNF-a) while enhancing anti-inflammatory responses via NF-kB pathway inhibition24

  • expert opinionShort peptides (EW, KE, EDP) bind to specific DNA sequences and histone proteins, influencing expression of immune-related genes24

  • expert opinionThymalin enhances natural killer cell activity and number, contributing to innate immune surveillance and anti-tumor responses24

  • expert opinionExact active peptide responsible for effects not definitively identified24

  • expert opinionThymalin is a natural or synthetic peptide thymomimetic with immunopharmacological effects25

  • expert opinionKey mechanisms of pineal peptides effect on thymus dystrophy is immunoendocrine cooperation, which is realized as transcription's activation of various proteins26

  • expert opinionThe key mechanisms of pineal peptides effect on thymus dystrophy is immunoendocrine cooperation, which is realized as transcription's activation of various proteins27

  • expert opinionIonizing radiation upon the human organism is accompanied by the formation of the secondary radiative immunodeficiencies, which can be treated with immunomodulating preparations28

  • theoreticalKE and EW dipeptides are active substances of Thymalin10

  • theoreticalEW reduces angiotensin-induced vasoconstriction and preserves endothelium-dependent vascular relaxation by inhibiting ACE2, the target protein of SARS-CoV-210

  • theoreticalThe immunomodulatory effect of Thymalin under the inflammatory response conditions in COVID-19 is based on the potential ability of its active components, EW and KE dipeptides, to regulate protein synthesis involved in the development of the cytokine storm10

  • theoreticalThymalin is a polypeptide complex isolated from the thymus and regulating the functions of the immune system12

  • theoreticalThymalin increases functional activity of T lymphocytes12

  • theoreticalThymalin acts on thymus-derived peptide receptors on T-cells19

  • theoreticalThe EW peptide shows energetically favorable binding to histone H1/3, altering chromatin conformation and gene accessibility23

  • theoreticalThe KE peptide demonstrates selective binding to TCGA DNA sequence motifs in gene promoter regions23

  • theoreticalThymalin is a synthetic peptide bioregulator that originates from the thymus gland30

  • theoreticalThymalin peptide mechanism of action involves stimulating the thymus gland, leading to increased production and maturation of T-lymphocytes30

  • theoreticalBy influencing gene expression, Thymalin supports cellular repair and regeneration, counteracting age-related cellular damage30

Dosing

Based on 1 animal finding and 7 expert opinion findings.

  • animalHigh efficiency of Thymalin can be attributed to the use of lower doses of the substance and their modulation during the treatment course in accordance with the regimes of activation therapy13

  • expert opinionStandard dosing in Russian clinical practice is 10 mg IM daily for 10 days per course18

  • expert opinionTwice-daily subcutaneous injections are required to maintain consistent plasma levels throughout a research protocol19

  • expert opinionDosing should be based on published immune endpoints (CD4+ counts, NK cell activity, antibody titers) rather than plasma half life optimization19

  • expert opinionStandard clinical protocol used in most Russian research studies; most effective dose22

  • expert opinionMorning injection for consistency; no stimulant effects so evening is also acceptable22

  • expert opinionIf combining with Epitalon, both can be injected at the same time or spaced 2-3 hours apart22

  • expert opinionRotate injection sites daily to prevent tissue irritation22

How the body handles it

Based on 4 human study findings and 7 expert opinion findings.

  • human studyThymalin accumulates in epithelial cells of human respiratory tract during early embryogenesis1

  • human studyThymalin is accumulated in epithelial cells of human respiratory tract during early embryogenesis3

  • human studyOriginal studies from the Khavinski Institute measured thymalin half life using radioimmunoassay methods tracking thymus-derived peptide fragments in rat and human plasma19

  • human studyRapid distribution with peak plasma concentration at 30–60 minutes post-injection and elimination half life between 6–8 hours19

  • expert opinionManufacturing of Thymalin uses special extraction and purification methods resulting in complete degradation of macromolecular proteins while preserving peptides with molecular weight under 10 kDa2

  • expert opinionThymalin half life is estimated at 6–8 hours based on Soviet-era pharmacokinetic studies and modern replications19

  • expert opinionThymalin half life is longer than thymosin alpha-1 (2–3 hours) but shorter than the pharmacodynamic duration of either peptide19

  • expert opinionThe complex is formulated as a lyophilized injectable solution for parenteral use20

Show the remaining 3

  • expert opinionThymalin demonstrates superior stability and biological activity compared to individual peptide components, with detectability and immune effects persisting for weeks post-administration20

  • expert opinionHalf-life: Variable based on peptide components20

  • expert opinionStability: Stable at refrigerated conditions (2-8°C) in sealed ampoules20

Safety and side effects

Based on 1 human study finding, 13 expert opinion findings, 2 anecdotal findings and 1 theoretical finding.

  • human studyThymalin and thymogen have practically no side effects1

  • expert opinionThymalin has an extensive safety record spanning over 40 years of documented clinical use with minimal reported adverse effects17

  • expert opinionOver 40 years of use in Russia is reportedly safe18

  • expert opinionThymalin has an excellent safety profile based on over 40 years of clinical use in Russia22

  • expert opinionSafety data comes primarily from Russian clinical studies and decades of medical use22

  • expert opinionSlight redness, warmth, or minor swelling at the injection site that typically resolves within a few hours22

  • expert opinionHigh-dose corticosteroids may reduce Thymalin's immune-stimulating effects; use together only under medical supervision22

  • expert opinionAntibiotics are safe to combine with Thymalin; many clinical protocols use them together for infections22

Show the remaining 9

  • expert opinionVitamin C is an antioxidant immune support; safe and complementary combination with Thymalin22

  • expert opinionProbiotics support immune health through different mechanisms; safe combination with Thymalin22

  • expert opinionIt is not approved by the FDA, EMA, or other Western regulatory agencies23

  • expert opinionExtract composition varies between batches (not a defined single compound)24

  • expert opinionNo FDA, EMA, or other Western regulatory approval24

  • expert opinionBovine-derived product carries theoretical contamination concerns24

  • anecdotalWell-tolerated after 5 days at starting dose with no side effects22

  • anecdotalExperiencing persistent injection site reactions22

  • theoreticalA theoretical prion contamination risk exists for animal-derived brain and gland tissue products18

What people use it for

Based on 7 human study findings, 22 expert opinion findings and 4 theoretical findings.

  • human studyThymalin is a polypeptide drug used for diseases associated with immune dysfunction, viral and bacterial infections, regeneration normalization, immunodepression, and depression of hematopoiesis after chemical and radiotherapy1

  • human studyRegulation of immunogenesis prevents development of cytokine storm in severe COVID-193

  • human studyThymalin is effective in various infectious diseases including hepatitis A and B, erysipelas, meningococcal infection, typhoid fever3

  • human studyThymalin is indicated for health maintenance and age-related pathology prevention in persons over 60 years old6

  • human studyThymalinum combined with norcolut and myelopidum was used to treat 55 patients with hyperplastic endometrial processes7

  • human studyThymalinum was used as an immunomodulator for psoriasis treatment8

  • human studyIn patients with severe COVID-19, the number of CD28, CD4, CD8 T lymphocytes in the blood decreased12

  • expert opinionThymalin is indicated for health maintenance and age-related pathology prevention in persons over 605

Show the remaining 25

  • expert opinionThymalin was originally developed in Russia to regulate immune function and delay aging16

  • expert opinionThymalin is effective against frequent illness or poor vaccine response16

  • expert opinionThymalin has been approved for medical use in Russia since the 1980s17

  • expert opinionIt has been used clinically in Russia for immune restoration but has never been evaluated by Western regulatory agencies18

  • expert opinionThymalin is approved in Russia for immune restoration indications18

  • expert opinionThymalin half life and polypeptide composition make it unsuitable for acute immune challenge scenarios requiring rapid onset19

  • expert opinionThymalin represents a targeted approach to counteracting age-related immune decline through restoration of thymic function and T-lymphocyte differentiation20

  • expert opinionThymalin treats immunocompromised states requiring immune enhancement20

  • expert opinionThymalin treats post-chemotherapy immune suppression20

  • expert opinionOlder individuals are more susceptible to severe COVID-19 due to age-related thymic involution, making Thymalin a potentially valuable therapeutic strategy21

  • expert opinionRussian thymic peptide complex that rejuvenates immune function and supports healthy aging22

  • expert opinionCombined peptide protocol for enhanced longevity and geroprotective effects22

  • expert opinionBoth Thymalin and Epitalon together produce stronger longevity and anti-aging effects than either alone; the most studied Thymalin combination22

  • expert opinionBoth support immune function through different mechanisms; combining is safe but may be redundant for some goals22

  • expert opinionZinc supports thymic function; combining with Thymalin is highly recommended22

  • expert opinionThymalin was first approved for clinical use in the USSR in 1982 for immunodeficiency states23

  • expert opinionThymalin can be used in the protective functions of the body in various dental diseases and pathology of organs and tissues of the maxillofacial region25

  • expert opinionThymalin has geroprotective effect on involution of pineal gland26

  • expert opinionThymalin is a thymic peptide with geroprotective effect on involution of pineal gland27

  • expert opinionPeptide preparations of thymos and bone marrow, referred to the cytomedinum class (thymalinum, thymogenum, haemalinum) were most perspective for the correction of the secondary radiative immunodeficiencies28

  • expert opinionThymalinum can be used in the treatment of radioactive affections of immune system28

  • theoreticalThymalin can be considered as an immunoprotective peptide drug for the prevention of COVID-1912

  • theoreticalThymalin is particularly valuable for individuals with compromised immune systems or those seeking to bolster their defenses against infections30

  • theoreticalThymalin is a sought-after peptide for anti-aging protocols30

  • theoreticalFor athletes and active individuals, Thymalin can be a valuable tool for enhancing recovery and maintaining peak immune function, especially during periods of intense training30

Other findings

Based on 1 human study finding and 13 expert opinion findings.

  • human studyThymalin is isolated from the calve thymus3

  • expert opinionThymalin is a medicinal drug based on a polypeptide complex isolated from the calve thymus4

  • expert opinionThymalin is one of the Khavinson Peptides, characterized by Prof. Khavinson from 1973 onwards, initially isolated from animal tissues and found to be organ specific11

  • expert opinionApproved for medical use in Russia since the 1980s16

  • expert opinionThymalin was developed in the Soviet Union in the 1970s by researchers Vladimir Khavinson and Vyacheslav Morozov17

  • expert opinionThymalin is an undefined mixture of peptides extracted from bovine (cow) thymus glands, developed in the Soviet Union in the 1970s18

  • expert opinionAs an undefined bovine tissue extract, Thymalin faces inherent challenges in batch-to-batch consistency and quality standardisation18

  • expert opinionOriginally developed in the 1970s at the USSR Institute of Gerontology20

Show the remaining 6

  • expert opinionMolecular Weight: 1,000-10,000 Da (heterogeneous mixture)20

  • expert opinionSequence: Short peptides (2-8 amino acids) from calf thymus20

  • expert opinionThymalin is a polypeptide complex originally isolated from the thymus gland of young calves, developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in Leningrad23

  • expert opinionThe EW dipeptide has molecular formula C16H19N3O5 and molecular weight 333.34 g/mol23

  • expert opinionThe overwhelming majority of published research originates from Khavinson's group and affiliated institutions, and independent replication by Western laboratories remains limited23

  • expert opinionApproved in Russia since the 1970s but not recognized by Western regulatory agencies24

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Single source

Almost all evidence comes from one Russian research group.

Multiple sources note that the overwhelming majority of Thymalin research originates from Vladimir Khavinson's laboratory and affiliated institutions, with limited independent replication by Western laboratories. One vendor states the effect rests on a single adequately-powered Russian RCT (n=266, PMID 14523363).

Limited evidence

Most human clinical data are observational, not blinded RCTs.

The large 266-person, 6–8 year dataset is repeatedly reported as observational; the COVID-19 comparison (n=36 vs n=44) and dramatic case-report figures (2-fold lymphocytes, 8-fold CRP reduction, etc.) are small and non-randomized. A vendor labels the n=266 study a 'single adequately-powered RCT', while the primary sources describe it as an observational study.

Other

Thymalin is an undefined, batch-variable bovine extract, not a single defined compound.

Vendor sources warn that Thymalin is an undefined mixture of peptides from calf thymus whose composition varies between batches, that the exact active peptide responsible for effects is not definitively identified, and that a theoretical prion/contamination risk exists for animal-derived tissue products.

Contested

Sources disagree on whether Thymalin is natural extract or synthetic.

Most sources describe Thymalin as a polypeptide complex extracted from calf thymus, but a tier-4 article calls it a 'synthetic peptide bioregulator' and another describes it as 'natural or synthetic'.

Contested

Approval/development dates vary across sources.

Sources variously state Thymalin was first approved in the USSR in 1982, in Russia since the 1980s, or since the 1970s; development is dated to the 1970s but one tier-2 study notes characterization from 1973 onwards. The registration number LS-000267 is dated February 26, 2010.

Single source

Half-life and pharmacokinetic figures come only from tier-3 vendor pages.

The 6–8 hour half-life, 30–60 minute peak, comparison to thymosin alpha-1 (2–3 hours), and 'weeks-long' detectability claims appear only in tier-3 vendor material (realpeptides.co, paragonsportsmedicine.com), with no primary pharmacokinetic study cited among the higher-tier sources.

Single source

The 45%/28% mortality figures appear only on one vendor site.

The specific 45% cardiovascular and 28% all-cause mortality reduction figures are reported only by a tier-3 vendor (thymalin-peptide.com), whereas the tier-1 primary studies express mortality effects as 2.0–2.1-fold (Thymalin) up to 4.1-fold (combined annual) reductions.

Other

CD28 fold-change reported slightly differently across sources.

The in vitro increase in CD28 (mature T-lymphocyte marker) is reported as 6.9-fold in one Khavinson source and 6.8-fold in the tier-2 study and vendor summary; CD44/CD117 reductions are given as 2.8-/2.2-fold in one place and '2–3 times' in another.

Safety and side effects

Safety and tolerability

A tier-1 review states that Thymalin and thymogen have practically no side effects (src-1). Multiple vendor sources report an extensive safety record over 40 years of documented clinical use in Russia with minimal reported adverse effects (src-8, src-9, src-11). A vendor protocol reports Thymalin is well-tolerated after 5 days at the starting dose, with occasional slight injection-site redness, warmth or minor swelling that typically resolves within a few hours, and advises daily site rotation; it notes that high-dose corticosteroids may reduce Thymalin's immune-stimulating effects (src-11).

Regulatory and quality caveats

Vendor profiles note Thymalin has no FDA, EMA or other Western regulatory approval (src-4, src-7). Vendor profiles also caution that as an undefined bovine tissue extract, Thymalin's composition varies between batches and carries a theoretical prion/contamination risk (src-4, src-8). One vendor notes the exact active peptide responsible for effects is not definitively identified. A vendor also states that Thymalin's half-life and polypeptide composition make it unsuitable for acute immune-challenge scenarios requiring rapid onset (src-10). One tier-2 in vitro study reports Thymalin could exert either protective or sensitizing action on radiation-induced cytogenetic effects in peripheral blood lymphocytes depending on concentration, cell radiosensitivity, radiation dose and relative biologic effectiveness (src-27), indicating dose- and context-dependent behavior.

Because almost all safety data derive from a single Russian research group and vendor material rather than independent blinded trials, the strength of the "practically no side effects" characterization should be weighed against the limited independent replication noted across sources.

Reconstitution and handling

Dosing

No dose has been established for this compound by any Western regulator. Vendor profiles note Thymalin has no FDA, EMA or other Western regulatory approval (src-4, src-7), though it is reported to be registered in Russia (registration number LS-000267 dated February 26, 2010, per src-3/src-6/src-7). The figures below are what sources report , not guidance.

  • A vendor reports that standard dosing in Russian clinical practice is 10 mg intramuscular daily for 10 days per course (src-8).
  • A vendor recommends twice-daily subcutaneous injections over a 10-20 day course to maintain consistent plasma levels, and advises dosing by immune endpoints (CD4+ counts, NK activity, antibody titers) rather than by plasma half-life (src-10).
  • A tier-2 animal study attributes Thymalin's reported high antitumor efficiency to use of lower-than-therapeutic doses modulated during the treatment course according to activation-therapy regimes (src-21).

Reconstitution and preparation

A vendor states Thymalin is formulated as a lyophilized injectable for parenteral use and is stable refrigerated at 2-8'C in sealed ampoules (src-12).

A vendor protocol (src-11) describes a 5-10 mg dosing tier with the following reconstitution arithmetic:

  • Reconstituting a 10 mg vial with 1 mL sterile water yields a concentration of 10 mg/mL.
  • At that concentration, a 5 mg dose corresponds to 0.5 mL.
  • The same protocol describes a morning injection with daily injection-site rotation, and advises spacing of 2-3 hours if co-injected with Epitalon.

Reported combinations

A vendor states the most studied Thymalin combination is with Epitalon for enhanced longevity/anti-aging effects, and lists zinc, vitamin C, probiotics and antibiotics as safe complementary combinations (src-11). Note that the large observational human dataset (src-2, src-19, src-30) studied Thymalin alongside Epithalamin rather than as monotherapy for its combined mortality figures.

Sources

Ordered by evidence quality — the strongest first.

  1. BioBRev2104004Khavinson.fm(opens in a new tab)
    Tier 1Web · khavinson.info
  2. Peptide bioregulators prolong human life(opens in a new tab)
    Tier 1Web · khavinson.info
  3. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  4. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients(opens in a new tab)
    Tier 1Web · khavinson.info
  5. Peptides of pineal gland and thymus prolong human life.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2003
  6. [Geroprotective effect of thymalin and epithalamin].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  7. Norcolut with immune modulators in the complex treatment for hyperplastic uterine processes.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1993
  8. Subpopulations of T lymphocytes in psoriasis patients and their changes during immunotherapy.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1987
  9. Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with thymalin: experimental and morphological study.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  10. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  11. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  12. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  13. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  14. Chornobyl catastrophe: cytogenetic effects of low dose ionizing radiation and their modification.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2016
  15. Peptides and Ageing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  16. Thymalin(opens in a new tab)
    Tier 3Web · thepreptide.com
  17. Thymalin — The Thymic Peptide for Immune Restoration and Longevity(opens in a new tab)
    Tier 3Web · thymalin-peptide.com
  18. Thymalin (Thymalin polypeptide complex) | PeptideTrace — PeptideTrace(opens in a new tab)
    Tier 3Web · peptidetrace.com
  19. Thymalin Half Life — Dosing, Storage & Protocols(opens in a new tab)
    Tier 3Web · realpeptides.co
  20. Thymalin Peptide | Immune & Aging Support(opens in a new tab)
    Tier 3Web · paragonsportsmedicine.com
  21. Thymalin Peptide in COVID-19: Evidence for Immune Support and Recovery(opens in a new tab)
    Tier 3Web · nbinno.com
  22. Thymalin Protocol — Complete Dosing & Administration Guide | Peptide Initiative(opens in a new tab)
    Tier 3Web · peptideinitiative.com
  23. Thymalin: Research Evidence & Safety Profile | PeptideInsight(opens in a new tab)
    Tier 3Web · peptideinsight.com · 2026
  24. Thymalin: 30 Studies Reviewed (2026) | PepCodex(opens in a new tab)
    Tier 3Web · pepcodex.com · 2026
  25. [Age features of bioregulatory therapy of dental diseases.].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  26. [Characteristics of the pineal gland and thymus relationship in aging].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2011
  27. [Influence of peptides from pineal gland on thymus function at aging].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2010
  28. [The correction of secondary radiation-induced immunodeficiencies].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 1991
  29. The Use of Thymalin for Immunocorrection and Molecular ...(opens in a new tab)
    Tier 4Web · pmc.ncbi.nlm.nih.gov
  30. Understanding Thymalin Peptide: Mechanism, Benefits, and Optimal Usage(opens in a new tab)
    Tier 4Web · nbinno.com